Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
Eli Lilly and Company
National Institute on Minority Health and Health Disparities (NIMHD)
Age
21–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Self-reported Hispanic and/or Latino heritage
Body Mass Index (BMI) 30-42 kg/m²
HbA1c ≤ 6.4%
You may not be if
Previous diagnosis of diabetes or fasting glucose ≥ 126 mg/dl or 2 hr oral glucose tolerance test plasma glucose ≥ 200 mg/dl
Unstable weight (≥4% during the last 2 months prior to study enrollment)
CPAP treatment for obstructive sleep apnea
Severe cardiovascular disease within the 6 months prior to study enrollment
Severe organ system dysfunction
Known clinically significant gastric emptying abnormality
History of chronic or acute pancreatitis
Thyroid-stimulating hormone (TSH) \>1.5X the upper limit of normal
Medical conditions that cause obesity
History of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder within the last 2 months
Active substance abuse with alcohol or drugs
Uncontrolled hypertension
Liver disease
Calcitonin level of ≥20 ng/L if eGFR ≥60 mL/min/1.73 m2 or ≥35 ng/L if eGFR \<60 mL/min/1.73 m2
Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
History of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
Severe anemia
Pregnant or breastfeeding
Metal implants that preclude MRI testing
Use of medications that are known to affect the study outcome measures
Do not agree to use contraception throughout the study period in male and female participants of reproductive and childbearing age
Persons who are not able to grant voluntary informed consent
Unable or unwilling to follow the study protocol
Have any other condition not listed in this section (e.g. hypersensitivity or intolerance) that is a contraindication of GLP-1R agonists
